Cambridge Healthtech Institute’s 11th Annual
Kinase Inhibitor Chemistry
April 14-15, 2020
Kinase inhibitor discovery is a very active area as developers are exploring more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications, such as inflammation and CNS disorders, as well as effectively harnessing allosteric modulators, and covalently binding compounds. This year will also be discussing the role of artificial intelligence, RNAs as drug targets, phosphatases, and protein degraders in kinase development. Cambridge Healthtech Institute’s 11th Annual Kinase Inhibitor Chemistry conference will once again bring together academic and industry leaders to network, collaborate and discuss advances in kinase inhibitor discovery and development.
NEW TARGETS & PROMISING CANDIDATES
Targeted Therapy in Patients with PIK3CA-Related Overgrowth Syndrome
Guillaume Canaud, MD, PhD, Professor of Medicine, Hospital Necker Enfants Malades, Paris
Comprehensive Evaluation of CDK Inhibitor Landscape in Cells
Carrow Wells, Research Associate, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
A Cdk9-PP1 Switch Regulates the Elongation-Termination Transition of RNA Polymerase II
Pabitra Parua, PhD, Research Fellow, Robert P. Fisher Lab, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
Interfering with the Immune System: DMXD-011, a Potential Treatment for Systemic Lupus Erythematosus (SLE)
Trevor Perrior, MA, PhD, FRSC, CEO, Domainex Limited
NEW TOOLS AND STRATEGIES
Artificial Intelligence in Kinase Inhibitor Discovery
Istvan J. Enyedy, PhD, Principal Scientist, Biogen
Discovery of Brain-Penetrant ASK1 Inhibitors for the Treatment of Neurological Diseases
Felix Gonzalez Lopez de Turiso, PhD, Team Leader, Medicinal Chemistry, Drug Discovery, Biogen
Targeting CDK Protein by Covalent Inhibitor and PROTAC Degrader
Tinghu Zhang, Scientist, Nathanael Gray Lab, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School
TARGETED KINASE DEGRADATION STRATEGIES
New Activities for Cereblon Modulators
Philip Chamberlain, DPhil, Executive Director, Structural and Chemical Biology, Celgene
So Many Ubiquitin Ligases and So Few PROTACs: Carving a New Path with Novel Ligases
Tauseef Butt, PhD, President and CEO, Progenra Inc.
Molecular Mechanisms of Small Molecule-Mediated Ubiquitin Ligase Targeting
Eric S. Fischer, PhD, Assistant Professor, Cancer Biology/Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute/Harvard Medical School
Targeting Focal Adhesion Kinase with PROTACs: From Tool to in Vivo
Joao Nunes, PhD, Investigator, Protein Degradation Group, Medicinal Science and Technology, GSK Medicine Research Centre
ADME Properties of PROTACs and Oral Bioavailability Improvement Strategies
Upendra Dahal, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.
* The program is subject to change without notice, due to unforeseen reason.